BRÈVE

sur ABIVAX (EPA:ABVX)

Abivax announces advances in its clinical program and updates its operations

Graphique de l'évolution du cours de l'action ABIVAX (EPA:ABVX).

Abivax provided an update on the status of its flagship clinical program, ABTECT. The phase 3 trial is evaluating Obefazimod for moderate to severe ulcerative colitis (UC). Patient recruitment is expected to be completed in early 2025, with initial results expected in the second quarter of 2025. Maintenance data is expected in the first quarter of 2026.

The company also announced progress in its preclinical program and appointments to key positions: Sylvie Grégoire as Chairman of the Board of Directors, Fabio Cataldi as Chief Medical Officer, and David Zhang as Chief Strategy Officer.

Abivax's cash position will be able to support its activities until the fourth quarter of 2025, thus ensuring the continuity of its clinical projects.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de ABIVAX